BioSpace News Archive

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report fourth quarter and 2020 financial results on Wednesday, February 3, 2021, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Company’s website at http://investor.aligntech.com.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter intellectual property (IP) connecting People and Things, today announced that its patent portfolio has grown 50% year-over-year, now comprising over 300 issued and pending U.S. and foreign patents – of which over 150 are related to Resonant’s groundbreaking 5G XBAR® technology.

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company’s common stock. The dividend is payable on March 9, 2021 to shareholders of record at the close of business on February 23, 2021 . The ex-dividend date i

Mirum Pharmaceuticals to Present at the 39 th Annual J.P. Morgan Healthcare Conference on January 12, 2021

Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secr

NextGen Biomed Ltd. (TASE: NXGN), which is in the process of merging with Scent Medical Technologies Ltd., reports that Scentech-Medical received approval from the Shamir Medical Center (Asaf Harofe) Review Board (Helsinki committee) for a new clinical trial.

Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 RESTORE trial for the treatment of patients with moderate-to-severe Crohn’s disease. These posi

Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) provided positive feedback during the company’s end of Phase 2 (EOP2) meeting for Bioniz’s BNZ-1.

Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt’s Amitiza ® (lubiprostone) 8 mcg and 24 mcg capsules. “This partnership brings the first Amitiza ® generic to patients—giving them a cost-e

Bryn Pharma, LLC (“Bryn” or the “Company”), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that results from its multi-dose study of BRYN-NDS1C (bi-dose epinephrine nasal spray), have been accepted for presentation at the 2021 American Acad